Table 2.

Number and percentage of RA patients presenting ILD under anti-TNFα treatment.

Total no. of RA patients	Patients developing ILD				References
	anti-TNFα N/%	Infliximab N/%	Etanercept N/%	Adalimumab N/%
10.649	299 (2.8%)	UN	UN	UN	Dixon et al., 2010 [26]
13.894	77(0.6%)	UN	77 (0.6%)	UN	Koike et al., 2011 [27]
5.000	25(0.5%)	UN	25 (0.5%)	UN	Takeuchi et al., 2008 [28]

ILD: interstitial lung disease; UN: unavailable.